Oculis (OCS) Scheduled to Post Earnings on Thursday

Oculis (NASDAQ:OCS) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Oculis to post earnings of ($0.52) per share for the quarter.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Stock Performance

NASDAQ OCS traded down $0.03 on Tuesday, hitting $17.56. 88,046 shares of the company’s stock traded hands, compared to its average volume of 36,273. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. Oculis has a 1-year low of $9.60 and a 1-year high of $18.00. The firm’s 50-day moving average price is $13.62 and its two-hundred day moving average price is $12.47. The firm has a market capitalization of $711.18 million, a PE ratio of -9.02 and a beta of -0.16.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis has a consensus rating of “Buy” and an average target price of $29.20.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.